Clinical trial

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of…

NCT00456586 · Kyowa Kirin, Inc., Industry · Completed

Key facts

NCT number NCT00456586
Title 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
Official title A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
Lead sponsor Kyowa Kirin, Inc., Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Parkinson's Disease
Intervention type Drug
Interventions KW-6002 (istradefylline)
Enrollment 180
Start date Apr 1, 2002
Primary completion May 1, 2003
Completion Jun 1, 2003
First posted Apr 5, 2007
Last update posted Apr 25, 2024
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies